MongoDB, Inc. (MDB) Stock Forecast
Data as of May 2, 2026Technology · Current price $263.20 (+4.98%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 3, 2026 | Daniel Ives | Wedbush | $380.00 | +44.4% |
| Mar 3, 2026 | Mike Cikos | Needham | $300.00 | +14.0% |
| Mar 3, 2026 | Keith Bachman | BMO Capital | $340.00 | +29.2% |
| Feb 25, 2026 | Rudy Kessinger | D.A. Davidson | $385.00 | +46.3% |
| Jan 5, 2026 | Matthew Martino | Goldman Sachs | $475.00 | +80.5% |
| Dec 2, 2025 | Rudy Kessinger | D.A. Davidson | $465.00 | +76.7% |
| Dec 2, 2025 | Hannah Rudoff | Piper Sandler | $490.00 | +86.2% |
| Dec 2, 2025 | Ittai Kidron | Oppenheimer | $450.00 | +71.0% |
| Dec 2, 2025 | Firoz Valliji | Bernstein | $452.00 | +71.7% |
| Nov 4, 2025 | Brad Reback | Stifel Nicolaus | $375.00 | +42.5% |
| Nov 4, 2025 | Keith Bachman | BMO Capital | $415.00 | +57.7% |
| Nov 4, 2025 | Rishi Jaluria | RBC Capital | $405.00 | +53.9% |
| Nov 3, 2025 | Miller Jump | Truist Financial | $400.00 | +52.0% |
| Sep 30, 2025 | Ryan MacWilliams | Wells Fargo | $430.00 | +63.4% |
| Apr 25, 2025 | Patrick Colville | Scotiabank | $160.00 | -39.2% |
| Mar 5, 2025 | Thomas Blakey | Cantor Fitzgerald | $344.00 | +30.7% |
| Mar 4, 2025 | Blair Abernethy | UBS | $350.00 | +33.0% |
| Dec 2, 2024 | Yun Kim | Loop Capital Markets | $400.00 | +52.0% |
| Aug 30, 2024 | Kash Rangan | Goldman Sachs | $340.00 | +29.2% |
| Aug 30, 2024 | Patrick Walravens | JMP Securities | $350.00 | +33.0% |
Top Analysts Covering MDB
MDB vs Sector & Market
| Metric | MDB | Technology Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.13 | 2.34 | 2.41 |
| Analyst Count | 70 | 13 | 18 |
| Target Upside | +57.0% | +4072.6% | +14.9% |
| P/E Ratio | -294.96 | 28.31 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-31 | $2.89B | $2.90B | $2.92B | 28 |
| 2027-04-30 | $762M | $777M | $800M | 12 |
| 2027-07-31 | $806M | $822M | $846M | 19 |
| 2027-10-31 | $851M | $868M | $893M | 10 |
| 2028-01-31 | $914M | $932M | $959M | 10 |
| 2028-04-30 | $915M | $933M | $960M | 15 |
| 2028-07-31 | $965M | $983M | $1.01B | 9 |
| 2028-10-31 | $1.01B | $1.03B | $1.06B | 9 |
| 2029-01-31 | $1.10B | $1.12B | $1.15B | 15 |
| 2030-01-31 | $5.06B | $5.15B | $5.31B | 7 |
| 2031-01-31 | $5.28B | $5.37B | $5.54B | 10 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-31 | $5.66 | $5.90 | $6.00 | 19 |
| 2027-04-30 | $1.46 | $1.49 | $1.55 | 10 |
| 2027-07-31 | $1.55 | $1.58 | $1.64 | 18 |
| 2027-10-31 | $1.82 | $1.87 | $1.94 | 10 |
| 2028-01-31 | $2.08 | $2.13 | $2.21 | 11 |
| 2028-04-30 | $1.89 | $1.94 | $2.01 | 16 |
| 2028-07-31 | $1.93 | $1.98 | $2.05 | 11 |
| 2028-10-31 | $2.27 | $2.33 | $2.41 | 11 |
| 2029-01-31 | $2.59 | $2.66 | $2.76 | 14 |
| 2030-01-31 | $9.44 | $9.65 | $10.05 | 2 |
| 2031-01-31 | $11.07 | $11.31 | $11.78 | 3 |
Frequently Asked Questions
What is the analyst consensus for MDB?
The consensus among 70 analysts covering MongoDB, Inc. (MDB) is Buy with an average price target of $413.36.
What is the highest price target for MDB?
The highest price target for MDB is $630.00, set by Ivan Feinseth at Tigress Financial on 2022-02-11.
What is the lowest price target for MDB?
The lowest price target for MDB is $160.00, set by Patrick Colville at Scotiabank on 2025-04-25.
How many analysts cover MDB?
70 analysts have issued ratings for MongoDB, Inc. in the past 12 months.
Is MDB a buy or sell right now?
Based on 70 analyst ratings, MDB has a consensus rating of Buy (2.13/5) with a +57.0% upside to the consensus target of $413.36.
What are the earnings estimates for MDB?
Analysts estimate MDB will report EPS of $5.90 for the period ending 2027-01-31, with revenue estimated at $2.90B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.